Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · IEX Real-Time Price · USD
3.190
+0.010 (0.31%)
At close: Apr 25, 2024, 4:00 PM
3.230
+0.040 (1.25%)
After-hours: Apr 25, 2024, 6:17 PM EDT
Acumen Pharmaceuticals Market Cap
Acumen Pharmaceuticals has a market cap or net worth of $191.65 million as of April 25, 2024. Its market cap has increased by 30.11% in one year.
Market Cap
191.65M
Enterprise Value
-21.05M
1-Year Change
30.11%
Ranking
Category
Stock Price
$3.19
Market Cap Chart
Since the IPO on July 1, 2021, Acumen Pharmaceuticals's market cap has decreased from $618.43M to $191.65M, a decrease of -69.01%. That is a compound annual growth rate of -34.03%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Apr 24, 2024 | 191.10M | 0.63% |
Apr 23, 2024 | 189.90M | 1.01% |
Apr 22, 2024 | 188.00M | -0.69% |
Apr 19, 2024 | 189.30M | -0.32% |
Apr 18, 2024 | 189.90M | -8.92% |
Apr 17, 2024 | 208.50M | -0.86% |
Apr 16, 2024 | 210.30M | -0.85% |
Apr 15, 2024 | 212.10M | -5.61% |
Apr 12, 2024 | 224.70M | -3.85% |
Apr 11, 2024 | 233.70M | 4.85% |
Apr 10, 2024 | 222.90M | -3.38% |
Apr 9, 2024 | 230.70M | -1.28% |
Apr 8, 2024 | 233.70M | 1.04% |
Apr 5, 2024 | 231.30M | 0.26% |
Apr 4, 2024 | 230.70M | -1.79% |
Apr 3, 2024 | 234.90M | 3.16% |
Apr 2, 2024 | 227.70M | -5.48% |
Apr 1, 2024 | 240.90M | -0.99% |
Mar 28, 2024 | 243.30M | -1.22% |
Mar 27, 2024 | 246.30M | 9.32% |
Mar 26, 2024 | 225.30M | -8.45% |
Mar 25, 2024 | 246.10M | -1.16% |
Mar 22, 2024 | 249.00M | -0.72% |
Mar 21, 2024 | 250.80M | 4.37% |
Mar 20, 2024 | 240.30M | 3.76% |
View and export this data all the way back to 2021.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Codexis | 209.50M |
Galectin Therapeutics | 202.12M |
Rigel Pharmaceuticals | 201.68M |
Zevra Therapeutics | 201.06M |
Innate Pharma | 199.68M |
bluebird bio | 197.08M |
908 Devices | 196.47M |
Compass Therapeutics | 195.05M |